Hwail Pharm화일약품
061250 · KOSDAQ · ₩061250 · 화일약품
₩5,750▼ ₩70 (1.20%)End-of-day · Oct 27, 2026 · End-of-day prices.
Income statement
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Revenue | ₩101B | ₩120B | ₩123B | ₩132B | ₩107B |
| Cost of sales | ₩94B | ₩109B | ₩111B | ₩118B | ₩96B |
| Gross profit | ₩6.6B | ₩11B | ₩12B | ₩14B | ₩11B |
| Operating income | −₩2.3B | ₩755M | ₩2B | ₩4.8B | ₩4.3B |
| Net income | −₩233M | ₩6.5B | ₩3.9B | −₩6.3B | ₩2.8B |
| Net income to shareholders | −₩233M | ₩6.5B | ₩3.9B | −₩6.3B | ₩2.8B |
Balance sheet
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Total assets | ₩213B | ₩216B | ₩186B | ₩186B | ₩194B |
| Current assets | ₩131B | ₩134B | ₩137B | ₩138B | ₩149B |
| Cash and equivalents | ₩61B | ₩54B | ₩67B | ₩45B | ₩39B |
| Total liabilities | ₩6.3B | ₩12B | ₩12B | ₩10B | ₩12B |
| Current liabilities | ₩6B | ₩12B | ₩11B | ₩7.9B | ₩12B |
| Borrowings | ₩0 | ₩4.2B | ₩2B | ₩2B | ₩6B |
| Total equity | ₩207B | ₩203B | ₩174B | ₩176B | ₩182B |
| Shareholders' equity | ₩207B | ₩203B | ₩174B | ₩176B | ₩182B |
Cash flow
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Cash from operations | ₩12B | ₩12B | ₩7B | −₩234M | ₩20B |
| Capital spending | ₩4B | ₩35B | ₩2B | ₩10B | ₩2.5B |
| Free cash flow | ₩7.9B | −₩23B | ₩5B | −₩11B | ₩18B |
Consolidated where available. Amounts in won.
Also known as: Hwail Pharm / 화일약품 / 061250 / KRX:061250
Source: KRX statistical information